Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression. [electronic resource]
Producer: 20160906Description: 2586-94 p. digitalISSN:- 1538-8514
- Androgen Antagonists -- administration & dosage
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- BCG Vaccine -- administration & dosage
- Cell Line, Tumor
- Cell Movement -- drug effects
- Cell Survival -- drug effects
- Curcumin -- administration & dosage
- Disease Progression
- Drug Synergism
- Female
- Flutamide -- administration & dosage
- Gene Expression -- drug effects
- Humans
- Integrin alpha5beta1 -- genetics
- Interleukin-6 -- genetics
- Macrophages -- drug effects
- Mice
- Receptors, Androgen -- metabolism
- Reverse Transcriptase Polymerase Chain Reaction
- Treatment Outcome
- Urinary Bladder Neoplasms -- drug therapy
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.